MedTrace Logo

Unraveling Mechanism of Action of Extracorporeal Photopheresis in Heart and Lung Transplant Patients

NCT06899828 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2025-03-28

No results posted yet for this study

Summary

This is a prospective observational single center national study. Lung and heart transplant patients with a definite diagnosis of chronic lung allograft dysfunction (CLAD) or cardiac allograft vasculopathy (CAV) will be assigned for extracorporeal photopheresis (ECP) as per common clinical practice to a 6-month ECP cycle with the aim of limiting progression of organ dysfunction. The exact mechanisms of ECP in chronic rejection after lung and heart transplantation (CLAD and CAV) are elusive but it is thought to induce apoptosis of lymphocytes and to generate regulatory T cells, which modulate transplant immune rejection by a complex effect.

Conditions

  • Heart Transplanted Patients
  • Lung Transplanted Patients
  • Chronic Lung Allograft Dysfunction (CLAD)
  • Cardiac Allograft Vasculopathy

Sponsors & Collaborators

  • Fondazione IRCCS Policlinico San Matteo di Pavia

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-17
Primary Completion
2024-07-31
Completion
2024-07-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06899828 on ClinicalTrials.gov